Zai Lab Ltd
About Zai Lab Ltd
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $457.2M
- Net income
- -$175.5M
- Total assets
- $1.2B
- Market cap
- $1.9B
- Gross margin
- 58.6%
- Operating margin
- -49.9%
- Net margin
- -38.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $460.2M
- Cost of revenue
- $190.5M
- Gross profit
- $269.6M
- Operating expenses
- $499.1M
- Operating income
- -$229.4M
- Income tax
- -$2.9M
- Net income
- -$175.5M
- EPS (basic)
- $-0.16
- EPS (diluted)
- $-0.16
Balance sheet
- Total assets
- $1.2B
- Current assets
- $1.0B
- Total liabilities
- $456.9M
- Current liabilities
- $416.2M
- Shareholders’ equity
- $715.5M
Cash flow
- Operating cash flow
- -$150.8M
- Investing cash flow
- $307.9M
- Financing cash flow
- $72.4M
- Net cash flow
- $229.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.9B
- EPS (diluted)
- $-0.16
- Shares outstanding
- 113.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 20, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $175.5M in FY2025.
- Revenue grew 840% from FY2020 to FY2025.
- Gross margin of 58.6%, net margin -38.1%.
- Trading 62% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Zai Lab Ltd.
Write a review
News about Zai Lab Ltd
News & sentiment via Polygon.io
